ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
Red Blood Cell Membrane Lipidomics: Potential Biomarkers Detecting Method for Plasma Volume Overload and Major Adverse Cardiovascular Events in Chronic Heart Failure Patients.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Correlation analysis of Serum NT-pro-BNP, IGFBP-7 and CTRP12 levels in chronic heart failure patients.Journal of medical biochemistry · 2026Article
- Red Blood Cell Membrane Lipidomics: Potential Biomarkers Detecting Method for Plasma Volume Overload and Major Adverse Cardiovascular Events in Chronic Heart Failure Patients.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Plasma volume fluctuations limit the utility of circulating lipidomics in chronic heart failure (CHF). In contrast, red blood cell (RBC) membrane lipidomics may serve as stable biomarkers that are unaffected by plasma volume changes. Two cohorts are included to investigate the association between RBC indicators and CHF. RBC membrane lipidomics is first used to characterize CHF and its impact on plasma volume overload (PVO) and major adverse cardiovascular events (MACE). The first cohort (n = 507,638) shows that the erythrocyte stress index (ESI), better than traditional RBC indicators, is associated with the prevalence of CHF with odds ratio (OR) and confidence interval (CI) of 1.57 (95% CI,1.55-1.59). ESI is also linked with in-hospital death in CHF. Another cohort (n = 1,550) indicated RBC membrane lipidomics ceramide subtype Cer 18:0;O2/16:0 and lysophosphatidylethanolamine subtype LPE 18:0 has an AUC of PVO with 0.75 and 0.61. The above two lipids are risk factors of PVO with OR of 1.62 (95% CI, 1.47-1.80) and 1.11 (95% CI, 1.06-1.16). They also are risk factors for MACE, with hazard ratios (HR) of 1.04 (95% CI, 1.01-1.07) and 1.06 (95% CI, 1.01-1.10). This research emphasizes the potential value of RBC membrane lipidomics for CHF development, prognosis, and treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.